Overview
BSC supports oncology clinical trials for both therapeutics and devices, including surgical oncology devices, radiation therapy systems, diagnostic technologies, and supportive care devices. Our experience spans solid tumors and hematologic malignancies.​
Specialized Capabilities

• Overall survival and progression-free survival endpoint design

• Adaptive designs for dose-finding and seamless Phase II/III trials

• Response evaluation criteria (RECIST, iRECIST) implementation

• Competing risks analysis for oncology outcomes

• Propensity score methods for real-world evidence studies​
  Regulatory Experience
  We understand oncology division expectations for time-to-event endpoints, interim analysis strategies, and appropriate alpha-spending approaches. Our team has experience with accelerated approval pathways, breakthrough therapy designations, and surrogate endpoint justification.​
  Representative Studies

• Surgical oncology devices (ablation, resection)

• Radiation therapy planning and delivery systems

• Cancer diagnostic and monitoring devices

• Supportive care technologies (pain management, symptom control)

• Minimal residual disease detection systems